- Home
- ANGX vs MNMD Comparison
ANGX vs MNMD Comparison
Compare ANGX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGX
- MNMD
- Stock Information
- Founded
- ANGX 2013
- MNMD 2019
- Country
- ANGX United States
- MNMD United States
- Employees
- ANGX N/A
- MNMD N/A
- Industry
- ANGX Movies/Entertainment
- MNMD Pharmaceuticals and Biotechnology
- Sector
- ANGX Consumer Discretionary
- MNMD Health Care
- Exchange
- ANGX Nasdaq
- MNMD Nasdaq
- Market Cap
- ANGX 960.8M
- MNMD 960.2M
- IPO Year
- ANGX N/A
- MNMD N/A
- Fundamental
- Price
- ANGX $5.34
- MNMD $11.08
- Analyst Decision
- ANGX Strong Buy
- MNMD Strong Buy
- Analyst Count
- ANGX 1
- MNMD 9
- Target Price
- ANGX $14.00
- MNMD $25.78
- AVG Volume (30 Days)
- ANGX 517.5K
- MNMD 2.0M
- Earning Date
- ANGX 11-13-2025
- MNMD 11-06-2025
- Dividend Yield
- ANGX N/A
- MNMD N/A
- EPS Growth
- ANGX N/A
- MNMD N/A
- EPS
- ANGX N/A
- MNMD N/A
- Revenue
- ANGX $242,655,179.00
- MNMD N/A
- Revenue This Year
- ANGX $197.90
- MNMD N/A
- Revenue Next Year
- ANGX $19.95
- MNMD N/A
- P/E Ratio
- ANGX N/A
- MNMD N/A
- Revenue Growth
- ANGX 110.21
- MNMD N/A
- 52 Week Low
- ANGX $3.77
- MNMD $4.70
- 52 Week High
- ANGX $60.00
- MNMD $14.43
- Technical
- Relative Strength Index (RSI)
- ANGX N/A
- MNMD 41.01
- Support Level
- ANGX N/A
- MNMD $10.82
- Resistance Level
- ANGX N/A
- MNMD $11.60
- Average True Range (ATR)
- ANGX 0.00
- MNMD 0.94
- MACD
- ANGX 0.00
- MNMD -0.19
- Stochastic Oscillator
- ANGX 0.00
- MNMD 9.42
About ANGX Angel Studios Inc. Class A Common Stock
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).